Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age

This study will look at how well Zostavax™ works in preventing shingles in participants ages 50-59 years old.

Inclusion Criteria:

• Must be between 50 - 59 years of age
• No fever on day of vaccination
• Females of reproductive potential must be willing to use acceptable form of birth control

Exclusion Criteria:

• Have received chicken pox or shingles vaccine
• Have already had shingles
• Have recently had another vaccination
• Pregnant or breast feeding. Have participated in another research study in the last 30 days
• You are taking certain antiviral drugs
• History of allergic reaction to any vaccine component, including gelatin or neomycin